- Home
- NKSH vs PROK Comparison
NKSH vs PROK Comparison
Compare NKSH & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKSH | PROK |
|---|---|---|
| Founded | 1891 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 248.5M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NKSH | PROK |
|---|---|---|
| Price | $35.37 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 38.6K | ★ 720.8K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ 100.81 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $8,176,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $45.36 | ★ N/A |
| Revenue Growth | 9.39 | ★ 1075.00 |
| 52 Week Low | $24.74 | $0.54 |
| 52 Week High | $40.00 | $7.13 |
Technical Indicators
Market Signals| Indicator | NKSH | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 45.39 |
| Support Level | $35.09 | $1.73 |
| Resistance Level | $38.24 | $2.58 |
| Average True Range (ATR) | 1.07 | 0.12 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 29.25 | 46.74 |
Price Performance
Historical ComparisonAbout NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.